Teva 2Q 2Q Revenue: $3.4 billion (+20%) 2Q Earnings: $521 million (-2%) Comments: Pharmaceutical sales in the quarter in North America were $2.1 billion (+36%). Sales in Europe were down 4% to $732 million. International sales were $481 million (+20%). Sales of Copaxone were up 21% in the quarter to $682 million. Sales of Azilect were $55 million (+31%). Sales in the women’s-health business, acquired from Barr, were $80 million (+4%). The increase reflected higher sales of the Pla...